presented by junzo hamanishi at 2014 asco annual meeting

24
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Upload: kort

Post on 23-Feb-2016

161 views

Category:

Documents


0 download

DESCRIPTION

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting. PD-1/ PD-L1 pathway in suppressing anti-tumor immunity . - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 2: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

PD-1/ PD-L1 pathway in suppressing anti-tumor immunity

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 3: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 3

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 4: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Nivolumab <br />(ONO4538/BMS936558)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 5: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Study design: Investigator initiated, 2 cohorts Phase II

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 6: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Key inclusion criteria

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 7: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Study schedule

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 8: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Demographics

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 9: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Adverse events: Regardless of causality <br /> (>=4 patients)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 10: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 10

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 11: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Serious adverse events<br />(Treatment-related)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 12: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Clinical Effect : Best Overall Response

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 13: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

A Responder with Serous adenoca : <br />Nivolumab 3mg/kg

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 14: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

A Responder with Clear cell carcinoma :<br />Nivolumab 3mg/kg

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 15: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Best overall responses in all patients

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 16: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Best overall responses in all patients in 2 cohorts

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 17: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Summary

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 18: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Conclusions

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 19: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Acknowledgements

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 20: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Research group

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 21: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 21

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 22: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Clinical Effect : Response Duration

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 23: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Best overall responses in all patients

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 24: Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 24

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting